These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 21857690)

  • 1. Abiraterone plus prednisone improves survival in metastatic castration-resistant prostate cancer.
    Tagawa ST; Beltran H
    Asian J Androl; 2011 Nov; 13(6):785-6. PubMed ID: 21857690
    [No Abstract]   [Full Text] [Related]  

  • 2. Abiraterone and its place in the treatment of metastatic CRPC.
    Sartor O; Pal SK
    Nat Rev Clin Oncol; 2013 Jan; 10(1):6-8. PubMed ID: 23149889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Compassionate use of abiraterone and cabazitaxel: first experiences in docetaxel-pretreated castration-resistant prostate cancer patients].
    Heck MM; Höppner M; Horn T; Thalgott M; Gschwend JE; Retz M
    Urologe A; 2012 Mar; 51(3):390-7. PubMed ID: 22331349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.
    Danila DC; Morris MJ; de Bono JS; Ryan CJ; Denmeade SR; Smith MR; Taplin ME; Bubley GJ; Kheoh T; Haqq C; Molina A; Anand A; Koscuiszka M; Larson SM; Schwartz LH; Fleisher M; Scher HI
    J Clin Oncol; 2010 Mar; 28(9):1496-501. PubMed ID: 20159814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [New treatments for castration-resistant prostate cancer].
    Sautois B; Gennigens C
    Rev Med Liege; 2013 Feb; 68(2):94-6. PubMed ID: 23469490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer.
    Attard G; Reid AH; Auchus RJ; Hughes BA; Cassidy AM; Thompson E; Oommen NB; Folkerd E; Dowsett M; Arlt W; de Bono JS
    J Clin Endocrinol Metab; 2012 Feb; 97(2):507-16. PubMed ID: 22170708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abiraterone and increased survival in metastatic prostate cancer.
    de Bono JS; Logothetis CJ; Molina A; Fizazi K; North S; Chu L; Chi KN; Jones RJ; Goodman OB; Saad F; Staffurth JN; Mainwaring P; Harland S; Flaig TW; Hutson TE; Cheng T; Patterson H; Hainsworth JD; Ryan CJ; Sternberg CN; Ellard SL; Fléchon A; Saleh M; Scholz M; Efstathiou E; Zivi A; Bianchini D; Loriot Y; Chieffo N; Kheoh T; Haqq CM; Scher HI;
    N Engl J Med; 2011 May; 364(21):1995-2005. PubMed ID: 21612468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Budgetary impact on a U.S. health plan adopting abiraterone acetate plus prednisone for the treatment of patients with metastatic castration-resistant prostate cancer.
    Sorensen S; Ellis L; Wu Y; Hutchins V; Linnehan JE; Senbetta M
    J Manag Care Pharm; 2013; 19(9):799-808. PubMed ID: 24156649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abiraterone and increased survival in metastatic prostate cancer.
    Berruti A; Pia A; Terzolo M
    N Engl J Med; 2011 Aug; 365(8):766; author reply 767-8. PubMed ID: 21864182
    [No Abstract]   [Full Text] [Related]  

  • 10. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.
    Fizazi K; Tran N; Fein L; Matsubara N; Rodriguez-Antolin A; Alekseev BY; Özgüroğlu M; Ye D; Feyerabend S; Protheroe A; Sulur G; Luna Y; Li S; Mundle S; Chi KN
    Lancet Oncol; 2019 May; 20(5):686-700. PubMed ID: 30987939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abiraterone acetate is well tolerated without concomitant use of corticosteroids.
    Attard G; Reid AH; de Bono JS
    J Clin Oncol; 2010 Oct; 28(29):e560-1; author reply e562. PubMed ID: 20805462
    [No Abstract]   [Full Text] [Related]  

  • 12. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).
    Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; Shore ND; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Van Poppel H; Carles J; Flaig TW; Efstathiou E; Yu EY; Higano CS; Taplin ME; Griffin TW; Todd MB; Yu MK; Park YC; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ; Saad F
    Eur Urol; 2014 Nov; 66(5):815-25. PubMed ID: 24647231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Abiraterone acetate: a novel therapeutic option in hormone-refractory prostate cancer].
    Turitto G; Di Bisceglie M; Moraca L; Sasso N; Sepede C; Suriano A; Romito S
    Recenti Prog Med; 2012 Feb; 103(2):74-8. PubMed ID: 22430753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting.
    Sartor O; Michels RM; Massard C; de Bono JS
    Oncologist; 2011; 16(11):1487-97. PubMed ID: 22048000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NICE guidance on abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen.
    Dyer M; Rinaldi F; George E; Adler AI
    Lancet Oncol; 2012 Aug; 13(8):762-3. PubMed ID: 23024987
    [No Abstract]   [Full Text] [Related]  

  • 16. Is abiraterone acetate well tolerated and effective in the treatment of castration-resistant prostate cancer?
    Antonarakis ES; Eisenberger MA
    Nat Clin Pract Oncol; 2009 Jan; 6(1):12-3. PubMed ID: 18957947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Novel agents for the therapy of castration-resistant prostate cancer: overview of pivotal studies and new strategies to come].
    Ouzaid I; Ravery V; Pouessel D; Culine S
    Prog Urol; 2013 Jan; 23(1):1-7. PubMed ID: 23287477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Commentary on: Abiraterone Plus Prednisolone in Metastatic, Castration-sensitive Prostate Cancer.
    Struss WJ; Black PC
    Urology; 2017 Nov; 109():1-2. PubMed ID: 28797683
    [No Abstract]   [Full Text] [Related]  

  • 19. The role of abiraterone in the management of metastatic castration-resistant prostate cancer.
    Rawlinson A; Mohammed A; Beatty J; Bell R; Miller M
    Expert Rev Anticancer Ther; 2012 Apr; 12(4):429-37. PubMed ID: 22500680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Agents that target androgen synthesis in castration-resistant prostate cancer.
    Ferraldeschi R; de Bono J
    Cancer J; 2013; 19(1):34-42. PubMed ID: 23337755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.